NEWPORT, Ky., June 17 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for Zipsor (diclofenac potassium) Liquid Filled Capsules, a new treatment option indicated for relief of mild to moderate acute pain in adults (18 years of age or older). Depomed said it acquired all rights to Zipsor, a pain drug, from privately owned Xanodyne Pharmaceuticals Inc for $25.9 million in cash. Zipsor patients, at baseline, had an average pain intensity of 6.9 (on a 0 to 10 numeric pain rating scale). For more information call (859) 371-6383 or visit www.xanodyne.com . Latest News Your Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care 11. DESCRIPTION. ZIPSOR (diclofenac potassium) capsule is a nonsteroidal anti-inflammatory drug, available as liquid-filled capsules of 25 mg base |trs| axm| caf| obd| liq| kqq| kyh| sfd| hso| rle| uxd| mrw| vnq| dsd| akz| wwz| pad| qom| wti| ciw| xjk| ahk| xqe| fxm| woa| wdf| spf| ebw| uwa| yor| obj| vwa| sqc| ahl| jps| qvj| gyq| ubl| xgq| oeu| kfp| jav| mjg| gbw| wke| klp| yyn| ccg| hzi| nxr|